Format
Items per page
Sort by

Send to:

Choose Destination

Results: 16

1.

The promise and perils of HDAC inhibitors in neurodegeneration.

Didonna A, Opal P.

Ann Clin Transl Neurol. 2015 Jan;2(1):79-101. doi: 10.1002/acn3.147. Epub 2014 Dec 3. Review.

2.

An investigation of diffusion imaging techniques in the evaluation of spinocerebellar ataxia and multisystem atrophy.

Rozenfeld MN, Nemeth AJ, Walker MT, Mohan P, Wang X, Parrish TB, Opal P.

J Clin Neurosci. 2015 Jan;22(1):166-72. doi: 10.1016/j.jocn.2014.08.006. Epub 2014 Nov 26.

PMID:
25439745
3.

The histone deacetylase HDAC3 is essential for Purkinje cell function, potentially complicating the use of HDAC inhibitors in SCA1.

Venkatraman A, Hu YS, Didonna A, Cvetanovic M, Krbanjevic A, Bilesimo P, Opal P.

Hum Mol Genet. 2014 Jul 15;23(14):3733-45. doi: 10.1093/hmg/ddu081. Epub 2014 Mar 4.

PMID:
24594842
4.

Giant axonal neuropathy-associated gigaxonin mutations impair intermediate filament protein degradation.

Mahammad S, Murthy SN, Didonna A, Grin B, Israeli E, Perrot R, Bomont P, Julien JP, Kuczmarski E, Opal P, Goldman RD.

J Clin Invest. 2013 May;123(5):1964-75. doi: 10.1172/JCI66387. Epub 2013 Apr 15.

5.

Explaining intermediate filament accumulation in giant axonal neuropathy.

Opal P, Goldman RD.

Rare Dis. 2013 Jun 17;1:e25378. doi: 10.4161/rdis.25378. eCollection 2013.

6.

LANP mediates neuritic pathology in Spinocerebellar ataxia type 1.

Cvetanovic M, Kular RK, Opal P.

Neurobiol Dis. 2012 Dec;48(3):526-32. doi: 10.1016/j.nbd.2012.07.024. Epub 2012 Aug 4.

7.

Vascular endothelial growth factor ameliorates the ataxic phenotype in a mouse model of spinocerebellar ataxia type 1.

Cvetanovic M, Patel JM, Marti HH, Kini AR, Opal P.

Nat Med. 2011 Oct 16;17(11):1445-7. doi: 10.1038/nm.2494.

8.

Cpd-1 null mice display a subtle neurological phenotype.

Kular RK, Gogliotti RG, Opal P.

PLoS One. 2010 Sep 9;5(9). pii: e12649. doi: 10.1371/journal.pone.0012649.

9.

Neuronal differentiation is regulated by leucine-rich acidic nuclear protein (LANP), a member of the inhibitor of histone acetyltransferase complex.

Kular RK, Cvetanovic M, Siferd S, Kini AR, Opal P.

J Biol Chem. 2009 Mar 20;284(12):7783-92. doi: 10.1074/jbc.M806150200. Epub 2009 Jan 9.

10.

Association of spinocerebellar ataxia type 3 and spinocerebellar ataxia type 8 microsatellite expansions: genetic counseling implications.

Paganoni S, Seelaus CA, Ormond KE, Opal P.

Mov Disord. 2008 Jan;23(1):154-5. No abstract available.

PMID:
17987652
11.

The role of LANP and ataxin 1 in E4F-mediated transcriptional repression.

Cvetanovic M, Rooney RJ, Garcia JJ, Toporovskaya N, Zoghbi HY, Opal P.

EMBO Rep. 2007 Jul;8(7):671-7. Epub 2007 Jun 8.

12.

Huntington's disease presenting as postsurgical psychosis.

Paganoni S, Naidech AM, Opal P.

Mov Disord. 2007 Jun 15;22(8):1209-10. No abstract available.

PMID:
17443707
13.

Generation and characterization of LANP/pp32 null mice.

Opal P, Garcia JJ, McCall AE, Xu B, Weeber EJ, Sweatt JD, Orr HT, Zoghbi HY.

Mol Cell Biol. 2004 Apr;24(8):3140-9.

14.

Mapmodulin/leucine-rich acidic nuclear protein binds the light chain of microtubule-associated protein 1B and modulates neuritogenesis.

Opal P, Garcia JJ, Propst F, Matilla A, Orr HT, Zoghbi HY.

J Biol Chem. 2003 Sep 5;278(36):34691-9. Epub 2003 Jun 14.

15.

The role of chaperones in polyglutamine disease.

Opal P, Zoghbi HY.

Trends Mol Med. 2002 May;8(5):232-6. Review.

PMID:
12067633
16.

Intrafamilial phenotypic variability of the DYT1 dystonia: from asymptomatic TOR1A gene carrier status to dystonic storm.

Opal P, Tintner R, Jankovic J, Leung J, Breakefield XO, Friedman J, Ozelius L.

Mov Disord. 2002 Mar;17(2):339-45.

PMID:
11921121
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk